We are live on ! Find out more
DMAQR

Deep Medicine Acquisition Corp. Rights
DMAQR

Delisted

DMAQR was delisted on the 31st of January, 2024.

Back to rankings

28 hedge funds and large institutions have $1.73M invested in Deep Medicine Acquisition Corp. Rights in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less funds holding

Funds holding: 33 → 28 (-5)

46% less capital invested

Capital invested by funds: $3.2M → $1.73M (-$1.47M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
28
Holders Change
-5
Holders Change %
-15.15%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
6
Closed
5
Calls
$334K
Puts
–
Net Calls
+$334K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$144K
2
UBS Group
UBS Group
Switzerland
+$177

Top Sellers

Rank Fund Capital Flow
1
OCM
Oaktree Capital Management
California
-$136K
2
CCM
Context Capital Management
California
-$63K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$46.3K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$12.6K
5
SCM
Saba Capital Management
New York
-$9.99K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAC
1
Cowen and Company
New York
$297K +$144K +570,348 +53%
MP
2
Mangrove Partners
Connecticut
$270K – – –
OCAM
3
Owl Creek Asset Management
New York
$135K – – –
YCM
4
Yakira Capital Management
Connecticut
$135K – – –
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$108K -$12.6K -50,000 -8%
SCM
6
Shaolin Capital Management
Florida
$91K – – –
KPF
7
K2 Principal Fund
Ontario, Canada
$85K – – –
AA
8
AQR Arbitrage
Connecticut
$67K – – –
WAM
9
Wolverine Asset Management
Illinois
$62K -$253 -1,000 -0.3%
HIM
10
HGC Investment Management
Ontario, Canada
$54K – – –
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$53K -$46.3K -183,200 -38%
MF
12
Magnetar Financial
Illinois
$52K -$2.33K -9,200 -3%
WA
13
Whitebox Advisors
Minnesota
$45K – – –
PC
14
Periscope Capital
Ontario, Canada
$43K – – –
CH
15
CVI Holdings
Delaware
$41K – – –
SCM
16
Saba Capital Management
New York
$38K -$9.99K -39,500 -16%
MTCM
17
Mint Tower Capital Management
Netherlands
$35K – – –
RCM
18
Rivernorth Capital Management
Florida
$27K – – –
Walleye Capital
19
Walleye Capital
New York
$25K – – –
SIA
20
SkyView Investment Advisors
New Jersey
$18K – – –
Walleye Trading
21
Walleye Trading
New York
$14K – – –
TCM
22
Tuttle Capital Management
Connecticut
$12K – – –
HF
23
HRT Financial
New York
$8K – – –
VF
24
Virtu Financial
New York
$6K -$105 -416 -1%
FLC
25
Fifth Lane Capital
Texas
$4K – – –
1
2

DMAQR Hedge Fund Activity: Q1 2022 in Review

28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q1 2022, worth a combined $1.73M — down 46% from $3.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of DMAQR and 0 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was Cowen and Company, adding an estimated $144K. The largest seller was Oaktree Capital Management, exiting entirely with an estimated $136K sold.

  • 28 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q1 2022, down from 33 in Q4 2021.
  • Funds reported $1.73M of Deep Medicine Acquisition Corp. Rights stock for Q1 2022, down 46% quarter-over-quarter.
  • 0 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q1 2022 and 5 closed out, a net change of -5 holders.
  • The largest Deep Medicine Acquisition Corp. Rights buyer in Q1 2022 was Cowen and Company, an estimated $144K added.
  • The largest Deep Medicine Acquisition Corp. Rights seller in Q1 2022 was Oaktree Capital Management, an estimated $136K sold.

Based on aggregated 13F filings for Q1 2022.